Summary-level data for NAFLD was obtained from a GWAS meta-analysis of 8,434 cases and 770,180 non-cases and another GWAS meta-analysis of 1,483 cases and 17,781 non-cases
Beyond danuglipron, we have early-stage candidates including our oral small molecule GIPR antagonist, which is in Phase II and has the potential to be used in combinations to drive weight loss, they told Tides Global
Ying W, Riopel M, Bandyopadhyay G, Dong Y, Birmingham A, Seo JB, et al
This allows us to gather information about your health history, including your cholecystectomy and any current digestive symptoms
Long Y, Tsai WB, Wangpaichitr M, Tsukamoto T, Savaraj N, Feun LG, Kuo MT
KarkarBahinSGneME